News

You can view the latest news, articles and announcements on EndoPredict below or visit our official Myriad Genetics press release page.

EndoPredict at SABCS – Prospective long-term and real-world data

December 16, 2022

Two prospective real-world studies presented at SABCS show EndoPredict accurately guides decisions on chemotherapy in ER+, HER2- breast cancer 12th December...

Watch Myriad Genetics' ESMO 2022 Industry Satellite Symposium

September 19, 2022

Should we use genetic signatures for chemotherapy decisions in ER+/HER2- premenopausal patients? Dr. Anastasia Constantinidou shares key new data from ESMO Con...

EndoPredict informs treatment decisions for premenopausal breast cancer

August 31, 2022

New publication shows EndoPredict Breast Cancer Prognostic Test accurately identified premenopausal women with ER+, HER2- breast cancer who could safely avoid ...

High adherence to EndoPredict test results in extended endocrine therapy decision making in early breast cancer

June 9, 2022

Clinicians demonstrated up to 100% adherence to EndoPredict test results in extended endocrine therapy decision making As a leader in genetic testing and ...